サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1781937

二重特異性抗体市場：薬剤タイプ別、適応症別、流通チャネル別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測

Bispecific Antibodies Market, By Drug Type, By Indication, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
二重特異性抗体市場：薬剤タイプ別、適応症別、流通チャネル別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測
出版日: 2025年06月04日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートのハイライト

二重特異性抗体市場規模は2024年に109億9,209万米ドルとなり、2025～2032年にかけてCAGR 40.10%で拡大

二重特異性抗体市場-市場力学

FDA承認の増加が市場需要を促進

米国FDAは2022～2024年の間に6つの二重特異性抗体を承認しており、革新的ながん治療に対する規制当局の支援の高まりを反映しています。その上、がん負担の増大が先進的免疫療法への需要を加速させており、二特異性抗体のような標的治療への投資を促しています。しかし、複雑な製造プロセスと高い開発コストが二特異性抗体市場の成長の課題となっています。それとは逆に、がん研究に対する政府の資金援助は技術革新の可能性を広げ、世界の二重特異性抗体市場に大きな成長機会をもたらしています。

二重特異性抗体市場-主要な洞察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2025～2032年）に約40.10%のCAGRで毎年成長すると推定されます。

薬剤タイプ別セグメンテーションでは、免疫グロブリンGが2024年に最大市場シェアを示すと予測されています。

適応症別では、がんが2024年の主要適応症でした。

地域別では、北米のが2024年に収益を生み出す主要市場となっています。

二重特異性抗体市場-セグメンテーション分析

二重特異性抗体の世界市場は、薬剤タイプ、適応症、流通チャネル、地域に基づいてセグメント化されます。

適応症別では、炎症性自己免疫疾患、がん、その他に分類されます。予測期間中、がん領域が大きな市場シェアを占めると予想されます。これは主に、世界のがん負担の増大と、腫瘍細胞を標的とし免疫反応を活性化する二重特異性抗体の臨床的成功によるものです。

同市場は、流通チャネル別にドラッグストア、小売薬局、病院薬局、オンライン薬局の4つに分類されます。病院薬局部門が大きな市場シェアを占めると予想されます。これは、二重特異性抗体が主にがんや自己免疫疾患のような複雑な病態に使用され、専門的な投与、モニタリング、入院治療が必要とされるためです。

二重特異性抗体市場-地理的洞察

北米の地域は、先進的ヘルスケアインフラ、旺盛な研究開発投資、米国FDAのような機関による早期の薬事承認が原動力となり、予測期間中、世界の二特異性抗体市場で主要な市場シェアを占めると予想されます。

一方、アジア太平洋のは、がん罹患率の上昇、臨床検査活動の活発化、医療アクセスの拡大、中国、インド、韓国などの国々におけるバイオ医薬品投資の増加により、最も速い速度で成長すると予測されています。

二重特異性抗体市場-競合情勢

標的免疫療法に対する需要の高まりは競合を激化させており、各社は技術革新、臨床開発、薬事承認に重点を置いた戦略をとる必要に迫られています。各社は、二特異性抗体フォーマットの強化、安全性プロファイルの改善、がんや自己免疫治療における有効性の向上のため、研究開発に多額の投資を行っています。戦略的提携、ライセンシング契約、新興市場への進出も主要なアプローチです。さらに、各社は先進的なプラットフォームや独自技術を活用することで、パイプラインの進捗を加速し、急速に進化する治療情勢の中で長期的な競合優位性を確保しています。

目次

第1章 二重特異性抗体市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 二重特異性抗体の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 二重特異性抗体産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長展望マッピング
  • 規制枠組み分析

第5章 二重特異性抗体市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 二重特異性抗体市場情勢

  • 二重特異性抗体市場シェア分析（2024年）
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 二重特異性抗体市場-薬剤タイプ別

  • 概要
    • 薬剤タイプ別セグメントシェア分析
    • 免疫グロブリンG
    • 非免疫グロブリンG

第8章 二重特異性抗体市場-適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • 炎症性と自己免疫疾患
    • がん
    • その他

第9章 二重特異性抗体市場-流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • ドラッグストア
    • 小売薬局
    • 病院薬局
    • オンライン薬局

第10章 二重特異性抗体市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析-二重特異性抗体産業

  • 競合ダッシュボード
    • 競合ベンチマーキング
    • 競合ポジショニング
  • 企業プロファイル
    • Amgen
    • Genentech
    • Akeso, Inc.
    • Taisho Pharmaceutical
    • Janssen
    • Immunocore
    • Adimab, Innovent Biologics, Inc.
    • AstraZeneca
    • Affimed GmbH
    • Xencor
    • F. Hoffmann-La Roche Ltd.
    • Sanofi
    • Regeneron Pharmaceuticals Inc.
    • Pieris Pharmaceuticals, Inc.
    • Eli Lilly
    • Mereo BioPharma Group plc
    • Merus
    • MacroGenics, Inc.
    • Sobi, TG Therapeutics Inc.
    • Genmab A/S
    • Alteogen
    • Emergent BioSolutions Inc.
    • Novartis AG
    • Astellas Pharma Inc.
    • Celgene Corporation
    • その他

第12章 アナリストの全方位的展望

目次
Product Code: ANV5388

REPORT HIGHLIGHT

Bispecific antibodies market size was valued at US$ 10,992.09 Million in 2024, expanding at a CAGR of 40.10% from 2025 to 2032.

Bispecific antibodies are engineered proteins designed to recognize and bind to two different antigens simultaneously. Unlike traditional monoclonal antibodies that target a single molecule, bispecific antibodies can engage two targets, such as a cancer cell and a T-cell, enhancing immune response and therapeutic precision. This dual-targeting ability makes them highly effective in treating complex diseases like cancer, autoimmune disorders, and infectious diseases, offering improved outcomes and reduced off-target effects.

Bispecific Antibodies Market- Market Dynamics

Increasing FDA approvals to propel market demand

The growing approval of bispecific therapies is driving market expansion, with the U.S. FDA approving 6 bispecific antibodies between 2022 and 2024, reflecting rising regulatory support for innovative cancer treatments. Besides, increasing cancer burden is accelerating demand for advanced immunotherapies, prompting investment in targeted therapeutics like bispecific antibodies. However, complex manufacturing processes and the high development costs continue to challenge bispecific antibodies market growth. On the contrary, government funding for cancer research is expanding innovation potential, which is providing massive growth opportunities for the global bispecific antibodies market.

Bispecific Antibodies Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 40.10% over the forecast period (2025-2032)

Based on Drug Type segmentation, immunoglobulin G was predicted to show maximum market share in the year 2024

Based on Indication segmentation, cancer was the leading Indication in 2024

On the basis of region, North America was the leading revenue generator in 2024

Bispecific Antibodies Market- Segmentation Analysis:

The Global Bispecific Antibodies Market is segmented on the basis of Drug Type, Indication, Distribution Channel, and Region.

The market is divided into three categories based on Indication: inflammatory & autoimmune disorder, cancer, and others. The cancer segment is expected to hold the major market share during the forecast period. This is primarily driven by the growing global cancer burden and the strong clinical success of bispecific antibodies in targeting tumor cells and activating immune responses.

The market is divided into four categories based on Distribution Channel: drug stores, retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies sector is expected to hold the major market share. This is because bispecific antibodies are primarily used in complex conditions like cancer and autoimmune diseases, which require specialized administration, monitoring, and inpatient care.

Bispecific Antibodies Market- Geographical Insights

The North America region is expected to hold the major market share in the global bispecific antibodies market during the forecast period, driven by advanced healthcare infrastructure, strong R&D investments, and early regulatory approvals by agencies like the U.S. FDA.

On the other hand, the Asia-Pacific region is projected to grow at the fastest rate, owing to rising cancer prevalence, increasing clinical trial activity, expanding healthcare access, and growing biopharmaceutical investments in countries such as China, India, and South Korea.

Bispecific Antibodies Market- Competitive Landscape:

Growing demand for targeted immunotherapies is intensifying competition, pushing companies to adopt strategies focused on innovation, clinical development, and regulatory approvals. Firms are investing heavily in R&D to enhance bispecific antibody formats, improve safety profiles, and increase efficacy in cancer and autoimmune treatments. Strategic collaborations, licensing deals, and expansion into emerging markets are also key approaches. Additionally, players are leveraging advanced platforms and proprietary technologies to accelerate pipeline progress and secure long-term competitive advantages in a rapidly evolving therapeutic landscape.

Recent Developments:

In March 2025, SanyouBio launched 73 bispecific antibody reference products covering approved and clinical-stage drugs, aiming to support drug development and address challenges by enabling dual-target binding to overcome limitations like resistance seen in single-target therapies.

In April 2025, Invenra Inc. announced the launch of its B-Body Express(TM) Antibody Expression service, allowing biotech and pharma companies rapid access to high-purity, validated bispecific antibodies from partner sequences, accelerating preclinical research with speed and advanced technology.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BISPECIFIC ANTIBODIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen
  • Genentech
  • Akeso, Inc.
  • Taisho Pharmaceutical
  • Janssen
  • Immunocore
  • Adimab, Innovent Biologics, Inc.
  • AstraZeneca
  • Affimed GmbH
  • Xencor
  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Regeneron Pharmaceuticals Inc.
  • Pieris Pharmaceuticals, Inc.
  • Eli Lilly
  • Mereo BioPharma Group plc
  • Merus
  • MacroGenics, Inc.
  • Sobi, TG Therapeutics Inc.
  • Genmab A/S
  • Alteogen
  • Emergent BioSolutions Inc.
  • Novartis AG
  • Astellas Pharma Inc.
  • Celgene Corporation
  • Others

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Immunoglobulin G
  • Non-Immunoglobulin G

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Inflammatory & Autoimmune Disorder
  • Cancer
  • Others

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Drug Stores
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bispecific Antibodies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bispecific Antibodies Market Snippet by Drug Type
    • 2.1.2. Bispecific Antibodies Market Snippet by Indication
    • 2.1.3. Bispecific Antibodies Market Snippet by Distribution Channel
    • 2.1.4. Bispecific Antibodies Market Snippet by Country
    • 2.1.5. Bispecific Antibodies Market Snippet by Region
  • 2.2. Competitive Insights

3. Bispecific Antibodies Key Market Trends

  • 3.1. Bispecific Antibodies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bispecific Antibodies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bispecific Antibodies Market Opportunities
  • 3.4. Bispecific Antibodies Market Future Trends

4. Bispecific Antibodies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bispecific Antibodies Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Bispecific Antibodies Market Landscape

  • 6.1. Bispecific Antibodies Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bispecific Antibodies Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. Immunoglobulin G
    • 7.1.3. Non-immunoglobulin G

8. Bispecific Antibodies Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 8.1.2. Inflammatory & Autoimmune Disorder
    • 8.1.3. Cancer
    • 8.1.4. Others

9. Bispecific Antibodies Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 9.1.2. Drug Stores
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Hospital Pharmacies
    • 9.1.5. Online Pharmacies

10. Bispecific Antibodies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bispecific Antibodies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bispecific Antibodies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bispecific Antibodies Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Bispecific Antibodies Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Bispecific Antibodies Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bispecific Antibodies Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Amgen
    • 11.2.2. Genentech
    • 11.2.3. Akeso, Inc.
    • 11.2.4. Taisho Pharmaceutical
    • 11.2.5. Janssen
    • 11.2.6. Immunocore
    • 11.2.7. Adimab, Innovent Biologics, Inc.
    • 11.2.8. AstraZeneca
    • 11.2.9. Affimed GmbH
    • 11.2.10. Xencor
    • 11.2.11. F. Hoffmann-La Roche Ltd.
    • 11.2.12. Sanofi
    • 11.2.13. Regeneron Pharmaceuticals Inc.
    • 11.2.14. Pieris Pharmaceuticals, Inc.
    • 11.2.15. Eli Lilly
    • 11.2.16. Mereo BioPharma Group plc
    • 11.2.17. Merus
    • 11.2.18. MacroGenics, Inc.
    • 11.2.19. Sobi, TG Therapeutics Inc.
    • 11.2.20. Genmab A/S
    • 11.2.21. Alteogen
    • 11.2.22. Emergent BioSolutions Inc.
    • 11.2.23. Novartis AG
    • 11.2.24. Astellas Pharma Inc.
    • 11.2.25. Celgene Corporation
    • 11.2.26. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us